Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at ...

Evotec listed three investors with stakes of 5% or greater in its 2023 annual report. At that time, T. Rowe Price was the ...

Shares in Evotec jumped as much as 13.3% on Monday after regulatory filings showed private equity firm Triton had built an over 9% stake in the German drug development company.

Any significant move would also need support from Evotec’s other major shareholders — Novo Holdings A/S, the parent company of drugmaker Novo Nordisk A/S, as well as Abu Dhabi sovereign fund Mubadala ...

Evotec agreed to sell its chemical API production facility ... Canadian drugmaker Apotex hired banks to prepare for its IPO.

Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market ...

Analyst Brendan Smith of TD Cowen maintained a Buy rating on Evotec AG (EVO – Research Report), with a price target of $10.00. Brendan ...

Evotec Ag (Adr) ( (EVO) ) has released its Q3 earnings. Here is a breakdown of the information Evotec Ag (Adr) presented to its investors.

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange ... m New technology development partnership with Novo Nordisk to support next-generation cell therapies ...